• Net revenues in Q1 2018 increased 18 percent over Q1 2017 to $16 million
• Total transaction dollars processed globally during Q1 2018 increased 51 percent to $839 million
• Named as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500
• Launched Netevia, a future-ready, multi-channel payments platform, to provide same business-day settlement and funding for merchants

Net Element, Inc. (NASDAQ: NETE), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment, continues to reach competitive milestones across all segments of its core business, according to the company’s May 15 conference call with investors (http://ibn.fm/urMo6). Financial results for the first quarter ended March 31, 2018, show that Net Element continues to experience organic growth, with net revenues increasing to $16 million, an increase of 18 percent over the same period last year.

“We are pleased to have made a strong start to the year, becoming more competitive for our sales partners and merchants while continuing to deliver growth,” Oleg Firer, CEO of Net Element, said during the call. “We expect to continue to improve growth across all segments during the year.”

First quarter highlights of 2018 are many, including the February 7 launch of Netevia, a proprietary, future-ready multi-channel payments platform. Connecting and simplifying payments across sales channels through a single integration point, Netevia delivers end-to-end payment processing through easy-to-use APIs. This model complements Net Element’s ability to perform in a multi-channel environment, including point-of-sale (POS), e-commerce and mobile devices. Other value-added services offered through the Netevia platform include fast, easy merchant account opening and integration, payment conversion optimization, over 150 risk-monitoring filters and highly competitive pricing for payment acceptance services.

Looking forward, Netevia will form part of the recently announced technology solution to connect with merchants and customers via an efficient blockchain technology enabled transaction processing ecosystem with an ability to build value-added services for platform users (http://ibn.fm/CW2ea). Net Element is a member of the prestigious Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative, with over 250 member companies. Net Element’s entrance into the EEA is complementary to many of the company’s initiatives, including its decentralized blockchain technology solution that will permit endless value-added services.

“Net Element is focused on delivering value-added solutions for our community as we develop decentralized blockchain solutions to connect merchants and consumers,” Firer said in announcing the company’s entry into the EEA. “Alongside leading global enterprises, such as Microsoft, Intel, JPMorgan, Samsung, ING, MasterCard, Thomson Reuters, Cisco Systems, and others, we have partnered with EEA to establish clear roadmap, robust governance model, and useful Ethereum resources.”

Net Element’s North American Transaction Solutions segment continues to generate the lion’s share of the company’s revenues, increasing 27 percent over the same period of the prior year to $14 million. The International Transaction Solutions segment brought in $2 million following the consolidation of the Online and Mobile Solutions segments during 2017.

“As previously stated in our recent press releases and our filings, the Company is in the best financial position in its history and poised for continued growth,” Firer informed investors during the conference call. “We are pleased to present the progress we have made during the first quarter and are working diligently to increase shareholder value by growing revenues, reducing expenses and creating proprietary payment services technology and services that benefit our merchants and their customers.”

For more information, visit the company’s website at www.NetElement.com

• ETST now begins 2017 fiscal year audit, which is required along with the approved Form 10 to uplist to the OTCQB
• Biotech company is focused on developing medical devices for the pharmaceutical and nutraceutical fields and marketing high-grade hemp cannabidiol (CBD)
• In a news release, Dr. Michel Aube, CEO and chief science officer of ETST, says that, following completion of audit, he sees investor confidence growing and ETST seeking to secure its first big round of financing

Earth Science Tech, Inc. (OTC: ETST) has announced completion of its audit for FY2015 and FY2016 and submitted its Form 10 to become fully reporting (http://ibn.fm/aHILK). ETST is now commencing its audit for FY2017. That audit and the approved Form 10 submission are required for an uplisting to the OTCQB Venture Market.

In a news release, Dr. Aube said, “We are in touch with institutional and private investors that were waiting for ETST to become a fully reporting company before investing the necessary amount to commercialize our projects. We can now resume our discussions with them.” He also said that transparency is a key tool in the growth of ETST’s business and gaining investor confidence.

Florida-based ETST is an innovative biotech company marketing a repositioned line of High Grade Full Spectrum cannabidiol.  Focused on manufacturing, marketing and distributing its cannabinoid products to the pharmaceutical and nutraceutical markets, it also conducts R&D on low cost, non-invasive medical devices.

Nickolas Tabraue, ETST director and president, added, “This is a major achievement for ETST, and becoming a fully reporting OTCQB company is going to open many opportunities while boosting investor confidence.”

ETST holds four wholly owned subsidiaries. One is Earth Science Pharmaceutical, which develops medical diagnostic tools and vaccines. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD is focused on manufacturing and distributing in the recreational space. Earth Science Foundation, Inc. is in the process of becoming a non-profit, and it will accept grants and donations to conduct further studies.

For more information, visit the company’s website at www.EarthScienceTech.com

• QuadSight™ technology improves night vision
• Eyes-On™ technology provides unique stereo vision advanced driver assistance
• Eye-Net™ technology offers real-time pre-collision alerts to vehicles and pedestrians

Seeing is believing, it’s been said, but we know that our eyes can’t always be trusted. For centuries, we hypothesized a geocentric universe, for example, based on seeing the sun ‘rising’ in the east and ‘setting’ in the west. Now we know that it’s only the moon that goes around the Earth. In our planetary system, the sun takes center stage. In more earthly matters, the same is true; we see things that are not there and fail to notice things that are, which is a huge problem if you’re operating a vehicle. So, Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) is out to help drivers see straight. The innovative Israeli company has developed technology that ‘sees’ a wider spectrum of frequencies than the human eye. The improved vision can only lead to safer driving.

Driving at night can be a challenge. To see objects, our eyes must detect the light reflected from them. The absence of daylight at night means reduced vision, because the intensity of light has decreased. But this doesn’t stop mosquitoes from biting at night, for they can ‘see’ the infrared ‘light’ reflected from our bodies and find us in the dark. Mosquitoes can detect frequencies in the electromagnetic spectrum that the human eye cannot, frequencies that resemble ‘heat’ much more than they do ‘light’. Being able to detect the heat radiation emitted by warm-blooded animals enhances the mosquito’s night vision. Infrared vision technology, like that being developed by FRSX, does the same. It improves vision by expanding the spectral range of detected radiation.

FRSX’s QuadSight technology is automotive vision, perfected. It sets a new bar for autonomous vehicle vision by achieving near 100 percent obstacle detection with near zero false alerts. The QuadSight System provides accurate obstacle detection under all weather and lighting conditions and comprises two sets of stereoscopic infrared and visible-light cameras, above the windshield, in the pattern: Infrared-Visible Light-Visible Light-Infrared on the front of the vehicle. QuadSight will detect obstacles, regardless of shape, form or material. Its sensors fuse the visible light and infrared radiation into a seamless 24/7 vision, while advanced algorithms perform 3D image analysis for accurate depth and obstacle detection.

FRSX has also developed Eye-Net, accident prevention technology that provides real-time pre-collision alerts to vehicles and pedestrians. The proprietary system uses a smartphone app that links to cloud-based servers operating on existing cellular networks, eliminating the need for additional designated hardware. Eye-Net goes beyond FRSX’s basic detection technology. It adds a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In early May 2018, FRSX announced that it had signed a merger agreement with Tamda Ltd. (TASE: TMDA) and its controlling shareholder, Ipax Issues Ltd. According to the agreement, Foresight will spin off its activities dedicated to the development of its Eye-Net accident prevention system into its wholly owned subsidiary, which will then merge with Tamda (http://ibn.fm/j4u4m).

FRSX also offers Eyes-On, a unique stereo vision Advanced Driver Assistance System (ADAS) that employs advanced algorithms for accurate depth analysis and obstacle detection. The Eyes-On system will detect all potential obstacles, including vehicles, cyclists, pedestrians, animals and inanimate objects, at a high degree of accuracy.

For more information, visit the company’s website at www.ForesightAuto.com

• Targeting combined cannabis market of 60 million adults
• Constructing cannabis grow facilities in California and Canada
• Diversified operations with cross-sector, cross-border footprints

The tide of cannabis legalization in North America is rising steadily to a flood, and nowhere is this more apparent than in the world’s two largest markets, California and Canada. The former was the first U.S. state to legalize (in 1996) medical marijuana, and, since January 1, 2018, has legally permitted marijuana for adult recreational use. In Canada, liberalization has followed a similar timeline. The Marihuana Medical Access Regulations (MMAR) were enacted in July 2001. They were superseded by the Marihuana for Medical Purposes Regulations (MMPR) in July 2013, which were then replaced in August 2016 by the current regime, the Access to Cannabis for Medical Purposes Regulations (ACMPR). Adult recreational use depends on the enactment of Bill C-45 (the Cannabis Act) by the Canadian House of Commons, which is expected before the end of summer. Together, these two markets comprise a colossal adult consumer base of around 60 million, divided equally at about 30 million each. It’s a base that Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) is targeting. The company currently has separate growing facilities under construction in these two markets, including the California Campus at Cathedral City, California, and the Canada Campus at Okanagan Falls, British Columbia.

With an economy that would place it at number six in a global GDP listing, California is now the world’s premier cannabis market. It’s a market that looks set to reach almost $4 billion in 2018. In addition, forecasts in Canada call for a market value of $1.7 billion by 2020.

Phase one of the California Campus, a 325,000 sq. ft. greenhouse in Cathedral City, is well underway. Sunniva expects the facility, with an estimated capacity of 60,000 kg annually at full production, including trim, will become operational in Q3 2018. Trim consists of leaves and other parts of the plant removed during pruning. A second phase, which will add another 164,000 sq. ft. and yield an expected 40,000 kg per year, is on the drawing board. Sunniva also has a state licensed extraction facility in operation capable of processing 500 lbs. (227 kg) of biomass a day, or 125,000 lbs. (56,700 kg) per year, into high margin drug delivery formats such as vape oil, capsules, tinctures and sprays. Sunniva’s U.S. subsidiaries now hold eight 10,000 sq. ft. cultivation licenses, one 22,000 sq. ft. cultivation license, one 22,000 sq. ft. nursery license, one 10,000 sq. ft. nursery license and two manufacturing licenses (http://ibn.fm/BNWje).

Additionally, Sunniva provides private label vaporizer devices to over 80 brands in California. At present, the company supplies only the hardware and packaging for these devices. However, it plans to fill the vaporizers with cannabis from its own facilities as soon as that is forthcoming, adding value to the products supplied to its white label clients.

Earlier in May 2018, Sunniva announced it had selected the 126-acre Okanagan Falls, British Columbia site at which to build its Canada Campus (http://ibn.fm/pA2GT). The 700,000 sq. ft. facility will have an expected output capacity of 100,000 kg annually, and it is anticipated to become operational in Q1 2019. About 75 percent of output will be pre-sold on a wholesale basis, with the rest sold directly to patients through its Natural Health Services (NHS) subsidiary. NHS, which operates a chain of seven medical marijuana clinics in Canada, has a patient base of some 95,000, which is served by 21 physicians. With so many footprints, Sunniva looks set to deliver the goods.

For more information, visit the company’s website at www.sunniva.com

• Recent U.S. Supreme Court ruling allowing states to legalize sports gambling aligns with FANDOM SPORTS’ emerging sports betting mobile atmosphere
• Company releases corporate update, points to multiple user acquisition strategies
• Revolutionary sports-centric social media platform able to measure, score and monetize opinionated dialogue
• Two-time Super Bowl Champion Byron Chamberlain joins FANDOM advisory group and content team
• Legal sports betting market currently estimated at more than $57 billion

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42) is applauding the U.S. Supreme Court’s landmark decision that overturns a 1992 federal ban on sports betting, opening the door for states to pass laws legalizing sports gambling. FANDOM SPORTS taps into the primal, unfiltered passion of sports fans with its uncensored social media platform delivered through the FANDOM SPORTS mobile app, and, with this ruling, it no longer needs to “Pick a Fight” with the U.S. Supreme Court, according to a company press release (http://ibn.fm/lALkP).

According to a Statista survey, almost 50 percent of people 18 years and older in the U.S. confess to placing a bet on a sporting event at least once in their lives (http://ibn.fm/w6c1B). Americans wager about $150 billion on sports each year illegally, according to the American Gaming Association (http://ibn.fm/wLWQ3), while the legal sports-betting market is worth about $57.6 billion.

“FANDOM SPORTS wishes to applaud the U.S. Supreme Court for definitely getting one right,” the company states in its release. “By setting an important precedent for states to now decide whether they want to regulate and legalize sports-related gambling, fans will now have a giant obstacle to their ultimate engagement removed.”

Through the FANDOM SPORTS App, which is currently available in the Google Play store for Android devices, avid fans of all sporting venues can interact, debate, argue, talk trash and instigate virtual rumbles as they connect with other sports fans from around the world. The company’s branding slogan of “Pick a Fight. Talk Trash. Get Rewarded” is no joke for passionate sports fans who thrive on unfiltered, raw sports talk that not only feeds primal sports passions, but encourages fans to pick a side or stand alone, all while earning bragging rights and virtual currency FANCOIN™ rewards that they can use on exclusive content, real-life experiences, swag and other gear.

According to the company’s latest corporate update (http://ibn.fm/sEw47), FANDOM SPORTS closed an over-subscribed funding round of approximately $3.3 million, completed a dramatic ‘brand refresh’ and, in mid-April, released the base model version of its first Android product. FANDOM SPORTS’ current priority is the placement of its FANCOIN app economy on a blockchain technology platform that will mitigate any operational risks associated with the gamification elements and peer-to-peer micro-betting features of upcoming product releases.

FANDOM SPORTS’ distribution strategy includes both on-the-ground, guerilla street marketing campaigns and various digital user acquisition initiatives. The v2 FANDOM SPORTS App will focus content creation on matches and games with an emphasis on real-life, absolute resolutions by providing a mechanism through which clear sides can polarize the discussion and fuel the FanFight wagering with micro-bets. Users, advertisers, potential FANCOIN redemption program affiliates and industry synergy partners will all find a home in the FANDOM SPORTS trash-talking arena.

For more information, visit the company’s website at www.FANDOMSPORTSMedia.com

• Global patents for innovative formulations and drug delivery platforms
• Strong development pipeline for cannabinoid-based pharmaceutical and nutraceutical products
• Capabilities to manufacture products of a quality unmatched by other industry players

Canadian biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) continues to strengthen its position in the cannabis industry through the development of its patent-protected bio-cannabis products. The company’s current initiatives are geared toward the manufacture and commercialization of its product pipeline in anticipation of cannabis legalization in Canada, the United States and other regulated international markets.

Pivot’s unique approach incorporates the acquisition of disruptive drug formulation and delivery technologies for use in the development of innovative bio-cannabis products. The company places a high premium on producing sustainable quality products, a focus that many other enterprises in the cannabis space lack. Through its proprietary drug delivery platforms, Pivot is able to develop high quality, industry-leading cannabinoid-based therapeutic products for the pharmaceutical and nutraceutical markets.

Pivot’s wholly owned subsidiary, Pivot Green Stream Health Solutions Inc. (“PGS”), is responsible for the research, development and commercialization of the company’s products. PGS has acquired global rights for several patented technologies, including BiPhasix™ transdermal drug delivery, Solmic oral solubilization, Thrudermic transdermal nanotechnology and Ready-to-Infuse-Cannabis (RTIC) powder-to-oil technology.

These proprietary technologies are deployed in the development of cannabidiol (CBD) and tetrahydrocannabinol (THC) based products. Pivot’s cannabinoid pipeline of pharmaceutical products includes two that use the Solmic drug delivery technology for cancer supportive care, targeting the relief of mucositis and chemotherapy-induced nausea and vomiting. The company has also deployed its Bi-Phasix™ delivery platform for the development of four products that target women’s sexual desire disorder, glaucoma, dysmenorrhea and dermatological conditions. Pivot’s development pipeline also contains products for the relief of restless leg syndrome, opioid withdrawal and the treatment of pain and inflammation.

The company’s Bi-Phasix™ drug delivery platform has been tested in human trials approved by both the FDA and EMA. This system has been proven to enhance the bioavailability of drugs and improve clinical outcomes. Apart from its focus on the pharmaceutical space, PGS is developing several CBD-based natural health products for the nutraceutical market, with the aim of acquiring the Natural Health Product (NHP) designation from Health Canada. This will enhance the marketability of these products, which require a shorter development cycle and offer opportunities for faster revenue generation.

In a recent product development update, Pivot announced that the development of its 1% CBD-based Oral Micelle Solution, in collaboration with the company’s German technology partner, Solmic GmbH, is complete, and the product is ready for market. This formulation employs Pivot’s patented delivery system to produce two topical creams to treat a variety of medical indications, most notably chemotherapy-induced nausea and vomiting.

The company’s patented formulations and drug delivery technologies have positioned it to assume a leading position in the cannabis industry. Pivot has the capabilities to generate products that will be unequalled in quality by any other licensed producer or product distributor. Global protection of its patents will enable the company to capitalize on international markets, establish a strong market position and deliver higher value for its shareholders.

For more information, visit the company’s website at www.PivotPharma.com

• Tracking global cannabis strain IPs through identification, registration and verification from genome to sale through a secure, proprietary blockchain technology platform
• Comprehensive, community-driven cannabis genetics archival platform
• BLOCKStrain combines traditional cannabis culture with modern cryptocurrency technology, compensating and rewarding those who contribute
• Multiple monetization channels, including strain/genetics registration, ongoing certification, strain marketplace/licensing, tracking/transactions and big data/deep learning
• Global cannabis market projected to reach $31.4 billion by 2021

BLOCKStrain Technology Corp. (TSX.V: SR.H), a full-service software company headquartered in Vancouver, BC, Canada, has developed the first integrated blockchain platform that registers and tracks cannabis intellectual property (“IP”) from genome to sale. It is proprietary, immutable and cryptographically secure, thereby establishing a single source of truth for cannabis strains and their ownership.

With Canada set to legalize marijuana use for recreational purposes, and other jurisdictions following suit around the world, new challenges will emerge regarding the ability to provide a safe and legal inventory of a product that up until now was largely only available on the black market. Cannabis will be heavily tested and regulated by numerous regulatory bodies in Canada. The cannabis industry faces unique challenges that BLOCKStrain specifically helps it address, including:

• Mandatory Testing: Through BLOCKStrain’s platform and lab-testing partners, the process is more efficient and streamlined, cutting the administrative burden in half and getting products to market faster;
• DNA Based Product Validation: The underlying blockchain technology creates a genetic fingerprint that identifies and validates the product electronically so any participant on the platform, including consumers, can view and track what’s happening with that product from genome to sale;
• Intellectual Property: Third, and perhaps most importantly, the BLOCKStrain platform protects the intellectual property of growers and breeders. This is important for the industry’s growth as products evolve and develop. If a craft grower, for example, creates a popular strain with unique characteristics, it will be able to protect its intellectual property by simply registering the strain’s genome with BLOCKStrain and locking that data into the blockchain. It will reside there forever and will be readily accessible in the event of future disputes, bringing a level of trust to the industry and ensuring licensing fees are paid to all players in the market.

Verification = Certification

BLOCKStrain’s genetics verification process is authentic and incredibly effective. User groups register by creating an account with BLOCKStrain, which starts the process. Organizations and independent growers submit seeds, flower and post-extraction product for testing to a registered and approved testing facility, which then submits test results to BLOCKStrain. Pre-existing data of genetic cannabis strains can also be submitted via BLOCKStrain verification administrators, with those results being added to the user group’s blockchain account. Submissions are entered into BLOCKStrain, and the transaction is completed and recorded.

Each time an item is tested and verified by the network, a Registration Affidavit is auto-generated and given a unique “BLOCKStrain Address” along with a traceable QR Code. Producers, patients and consumers are able to not only verify the test but can also rate the product, write reviews and share opinions. This detail is stored within BLOCKStrain and, just like the test results, cannot be tampered with or modified. Verification and certification are earned by all parties for their participation.

Safe Consumer Supply

BLOCKStrain demystifies the seed-to-sale process for all relevant stakeholders including producers, distributors, shippers, government agencies and consumers by creating a repository of cannabis genomes on an immutable, shared ledger. Thousands of cannabis strains exist and cultivators are breeding new strains all the time. The proliferation of cannabis strains can prove problematic for consumers since there are more than 500 known chemical compounds in a single plant. Furthermore, since several dozens of these compounds have been identified as pharmacologically active, it becomes more and more difficult for consumers to know what they are purchasing.

It is for this reason that being able to quantify the genetics, potency and equivalencies among cannabis products is crucial to the future of legalized cannabis. The difference is not so much in the name or brand attached to the cannabis, but the DNA of the plant itself. BLOCKStrain ensures product integrity, safety, regulatory compliance, product licensing and authenticity – all vital elements for the emerging cannabis industry.  This technology also bolsters the process of meeting government regulatory standards by providing real-time visibility of industry operations to agencies assigned to enforce and regulate cannabis activity.

Intellectual Property Rights

BLOCKStrain allows for the defense of intellectual property rights for the grower with an authentic, verifiable chain of evidence embedded in the blockchain itself. Proof of ownership for a specific strain of cannabis is paramount in a multibillion dollar industry. Real life ownership disputes have already begun in the industry with legal battles underway. Unfortunately, the framework for resolving these disputes has yet to be defined and they are not likely to be resolved anytime soon.

Consumers and regulators alike want to know whether a cannabis product grown and sold at a local dispensary is safe and meets quality control standards. BLOCKStrain enhances trust of origin from genome-to-sale as cannabis flows through the supply chain, verifying critical steps in the process such as who is growing the plant, which seed is planted and where did it come from, whether pesticides were used, how much was grown, which tests are used to establish quality and potency, where the product is transported and how, and whether possession limits are meeting regulatory standards.

In summary, BLOCKStrain has developed the most comprehensive, secure and community-driven cannabis genetics archival platform for cannabis breeders and growers, large and small, to protect and release their varieties into the public domain, all while compensating and rewarding them for their contributions.

For more information, visit the company’s website at www.BLOCKStrain.io

• CIIX recently announced the launch of Bitcoin Talk Show
• Bitcoin Talk Show is one part of a larger strategic plan to provide Chinese-speaking investors with investment education and trading tools
• Company focused on being a leader in financial information and education

ChineseInvestors.com, Inc. (OTCQB: CIIX), a fintech company providing Chinese-speaking investors financial education, recently announced the launch of a cryptocurrency and blockchain talk show titled “Bitcoin Talk Show.” This new program will begin airing the first week of June 2018 on the Phoenix North America Chinese Channel. The 22-minute talk show has entered into a contract to air monthly for one year and broadcast to audiences in North America, as well as to be aired on the ChineseFN and Newcoins168.com YouTube channels.

The launch of Bitcoin Talk Show is only one key part of the company’s strategic plan to provide Chinese investors with essential cryptocurrency investment education and trading tools. CIIX provides real-time market commentary, analysis and education-related services in Chinese language character sets and is set to expand into retail facing services. The company’s platforms include:

• Bitcoin Multimillionaire, the first daily cryptocurrency newscast from the New York Stock Exchange in the Chinese language, which was launched in 2017;
• www.NewCoins168.com, a free cryptocurrency and blockchain website providing the latest news and investment education in the Chinese language, which was launched in November 2017;
• Bitcoin Talk Show, to be aired on Phoenix North America, a free channel offered by Time Warner Cable, and available on YouTube beginning the first week of June 2018;
• Bitcoin Trading Academy LLC, set to launch in June 2018, which will offer online and live courses focused on basic knowledge about bitcoin, alternative cryptocurrencies and vetting new coin offerings (Additional course offerings can be found at www.NewCoins168.com); and
• CIIX intends to acquire XBTeller.com and its nine ATM locations throughout Colorado in order to expand its current cryptocurrency and blockchain business to include retail-facing services.

CIIX recently spun off its ventures in the cannabis industry into a private company to focus solely on its initial vision of financial consulting. “As the company continues its expansion into the cryptocurrency space, we anticipate a 30% increase in revenues from last year, resulting in three consecutive years of revenue growth since 2016. This is an exciting time for ChineseInvestors.com, Inc. as the company’s fiscal year comes to an end on May 31, 2018,” Warren Wang, CEO of ChineseInvestors.com, Inc., stated in a news release. CIIX’s growing portfolio of platforms strengthens the company’s focus and reputation as a leader in financial information for the Chinese-speaking community.

For more information, visit the company’s website at www.ChineseInvestors.com

• Online virtual banking for licensed cannabis providers offers solution to traditional banking’s lack of support
• REFG is a first-tier merchant processing and comprehensive digital services company that creates a cashless environment for cannabis providers
• Its integrated gateway ‘Green’ is a FinCEN compliant system that also tracks sales and tax collection and offers management features for bill payments – from payroll to vendor invoices

Medical Cannabis Payment Solutions Inc.’s (OTC: REFG) Green is a comprehensive and digital processing system that offers cannabis merchants online signup and banking, solving the problem of little or no support by traditional banks for the cannabis industry. Green is an end-to-end management system in the state-legalized cannabis markets.

REFG offers both licensed dispensaries and retail merchant clients its unique online financial processing system called Green, creating a secure and efficient cashless digital world of banking. It also offers a solution to cannabis patients and retail customers who wish to purchase product using virtual currency, such as bitcoin.

Green has produced a virtual banking system alternative. For bitcoin transactions, REFG has partnered with First Bitcoin Capital Corporation – a solution tailored for the industry. According to a report by CNBC, a majority of traditional banks still will not work with medical cannabis companies (http://ibn.fm/OzKAR). That makes REFG’s solution unique and vital in the cannabis market, solving the issue of having to handle excessive cash within licensed dispensaries.

Traditional banks and even credit cards, such as Visa or MasterCard, do not accept financial transactions dealing with federally controlled substances. Green is fully FinCEN compliant and a top-tier level 1 payment processor.

Green also offers clients the ability to handle management of all financial transactions, including accounts payable, deposits, payroll and any other expenses.

For more information, visit the company’s website at www.Take.Green

• Expanding the applicability of edible delivery technology within the drug industry
• Creating strategic partnerships through licensing agreements
• Breakthrough in nicotine absorption study supports further investigation into the many possible uses beyond the cannabis and nicotine industries

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, partners with leading companies within the drug industry.  The company is known primarily for removing objectionable flavors while improving the effectiveness of gastro-intestinal delivery of edible cannabinoid consumer products, but the company is now working to expand the applicability of its technology beyond the cannabis industry. DehydraTECH™ is Lexaria’s edible delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules.

This revolutionary technology makes it possible to deliver bioactive substances via oral ingestion, eliminating the need for unhealthy practices of inhalation or the addition of unhealthy sugars or sweeteners that are commonly used to mask taste. The implications are widespread and promise improvements in the delivery of NSAIDs and vitamins, as well as nicotine and more. The company is strategically positioned with patents issued in the U.S. and Australia (and more pending in over 40 countries) to enhance products and companies already established within their industry.

LXRP is disrupting the delivery of drugs or other active ingredients by strategically partnering, not competing, with industry leaders. The company recently announced a major new licensing agreement with Nuka Enterprises LLC. This 10-year agreement gives Nuka and its “1906” brand of cannabis chocolates a competitive technology advantage and increases the use of DehydraTECH™ from chocolate to candies, beverages, capsules, pills and topical creams. The company also entered into a five-year semi-exclusive rights agreement to use DehydraTECH™ for cannabis beverage applications in California with GP Holdings LLC.

LXRP’s research and interest go beyond the cannabis industry. Lexaria’s patented DehydraTECH™ is currently being analyzed in the lab for nicotine delivery. The findings suggest a prolongation of nicotine’s effectiveness with the Lexaria formulation, which may also be beneficial in controlling cravings over an extended period of time with smaller and fewer edible nicotine doses. This is good news for LXRP and its proprietary technology. The findings suggest that further investigation needs to be done into whether the technology could be used to help reduce unwanted side effects common to other drugs.

The possibility of partnerships reaches far beyond these two industries. Research efforts have shown the edible technology to be compatible with a wide range of consumer-related compounds. Higher bioavailability of drugs is often associated with lower overall doses of certain molecules, which pass on cost reduction to consumers as well as bypassing unwanted side effects of the drugs. This revolutionary technology is disrupting the delivery of drugs, allowing the consumer to ingest less of the harmful byproducts while enhancing the benefits.

For more information, visit the company’s website at www.LexarioBioscience.com